Literature DB >> 15520002

Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides.

Atsushi Suenaga1, Naoki Takada, Mariko Hatakeyama, Mio Ichikawa, Xiaomei Yu, Kentaro Tomii, Noriaki Okimoto, Noriyuki Futatsugi, Tetsu Narumi, Mikako Shirouzu, Shigeyuki Yokoyama, Akihiko Konagaya, Makoto Taiji.   

Abstract

Ligand-activated and tyrosine-phosphorylated ErbB3 receptor binds to the SH2 domain of the p85 subunit of phosphatidylinositol 3-kinase and initiates intracellular signaling. Here, we studied the interactions between the N- (N-SH2) and C- (C-SH2) terminal SH2 domains of the p85 subunit of the phosphatidylinositol 3-kinase and eight ErbB3 receptor-derived phosphotyrosyl peptides (P-peptides) by using molecular dynamics, free energy, and surface plasmon resonance (SPR) analyses. In SPR analysis, these P-peptides showed no binding to the C-SH2 domain, but P-peptides containing a phospho-YXXM or a non-phospho-YXXM motif did bind to the N-SH2 domain. The N-SH2 domain has two phosphotyrosine binding sites in its N- (N1) and C- (N2) terminal regions. Interestingly, we found that P-peptides of pY1180 and pY1241 favored to bind to the N2 site, although all other P-peptides showed favorable binding to the N1 site. Remarkably, two phosphotyrosines, pY1178 and pY1243, which are just 63 amino acids apart from the pY1241 and pY1180, respectively, showed favorable binding to the N1 site. These findings indicate a possibility that the pair of phosphotyrosines, pY1178-pY1241 or pY1243-pY1180, will fold into an appropriate configuration for binding to the N1 and N2 sites simultaneously. Our model structures of the cytoplasmic C-terminal domain of ErbB3 receptor also strongly supported the speculation. The calculated binding free energies between the N-SH2 domain and P-peptides showed excellent qualitative agreement with SPR data with a correlation coefficient of 0.91. The total electrostatic solvation energy between the N-SH2 domain and P-peptide was the dominant factor for its binding affinity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520002     DOI: 10.1074/jbc.M410436200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  An improved method to predict the entropy term with the MM/PBSA approach.

Authors:  Jacob Kongsted; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2008-09-10       Impact factor: 3.686

3.  In silico prediction of ErbB signal activation from receptor expression profiles through a data analytics pipeline.

Authors:  Arya A Das; Elizabeth Jacob
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

4.  Vascular endothelial growth factor receptor 1 contributes to Escherichia coli K1 invasion of human brain microvascular endothelial cells through the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Wei-Dong Zhao; Wei Liu; Wen-Gang Fang; Kwang Sik Kim; Yu-Hua Chen
Journal:  Infect Immun       Date:  2010-08-30       Impact factor: 3.441

5.  Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor.

Authors:  Atsushi Suenaga; Mariko Hatakeyama; Anatoly B Kiyatkin; Ravi Radhakrishnan; Makoto Taiji; Boris N Kholodenko
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

6.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.

Authors:  Byung-Kwon Choi; Xiumei Cai; Bin Yuan; Zhao Huang; Xuejun Fan; Hui Deng; Ningyan Zhang; Zhiqiang An
Journal:  Protein Cell       Date:  2012-09-15       Impact factor: 14.870

9.  Structural and functional basis of a role for CRKL in a fibroblast growth factor 8-induced feed-forward loop.

Authors:  Ji-Heui Seo; Atsushi Suenaga; Mariko Hatakeyama; Makoto Taiji; Akira Imamoto
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

Review 10.  Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.

Authors:  Heidi M Haikala; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2021-02-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.